"PAI is a market leader in RTU oral liquid medicines, and that same focus on quality, reliability, and patient-centric design carries naturally into RTU injectables," said Kurt Orlofski, CEO of PAI ...
Par Health, Inc. ("Par Health" or the "Company") today announced the appointment of Dr. William ("Bill") Larkins as Executive ...
This agreement reinforces Credence’s role as a trusted partner to the pharmaceutical industry in advancing patient care. This ...
Drug shortage relief targeted as PAI Pharma acquires Nivagen to expand domestic sterile injectable production in Sacramento, Calif.
PAI Pharma acquires Nivagen Pharmaceuticals; expands domestic sterile injectable production and ready-to-use products: Greenville Friday, January 9, 2026, 12:00 Hrs [IST] PAI Phar ...
April 25 (Reuters) - West Pharmaceutical Services (WST.N), opens new tab on Thursday beat quarterly profit estimates and raised its annual profit forecast, banking on rising demand for cartridges and ...
Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. For $20 million upfront, ...
Headquartered in Greenville, South Carolina, PAI is a developer, manufacturer and marketer of oral liquid medicines.
West Pharmaceutical Services, Inc. (NYSE:WST) is included among the 14 Best Dividend Growth Stocks to Buy and Hold in 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback